Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
Publication
, Journal Article
Halabi, S; Rini, BI; Escudier, B; Stadler, WM; Small, EJ
Published in: Cancer
June 1, 2015
Duke Scholars
Published In
Cancer
DOI
EISSN
1097-0142
Publication Date
June 1, 2015
Volume
121
Issue
11
Start / End Page
1906
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Kidney Neoplasms
- Interferon-alpha
- Humans
- Female
- Carcinoma, Renal Cell
- Antineoplastic Combined Chemotherapy Protocols
- 4206 Public health
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Rini, B. I., Escudier, B., Stadler, W. M., & Small, E. J. (2015). Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer, 121(11), 1906. https://doi.org/10.1002/cncr.29252
Halabi, Susan, Brian I. Rini, Bernard Escudier, Walter M. Stadler, and Eric J. Small. “Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?” Cancer 121, no. 11 (June 1, 2015): 1906. https://doi.org/10.1002/cncr.29252.
Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 1;121(11):1906.
Halabi, Susan, et al. “Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?” Cancer, vol. 121, no. 11, June 2015, p. 1906. Pubmed, doi:10.1002/cncr.29252.
Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 1;121(11):1906.
Published In
Cancer
DOI
EISSN
1097-0142
Publication Date
June 1, 2015
Volume
121
Issue
11
Start / End Page
1906
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Kidney Neoplasms
- Interferon-alpha
- Humans
- Female
- Carcinoma, Renal Cell
- Antineoplastic Combined Chemotherapy Protocols
- 4206 Public health
- 3211 Oncology and carcinogenesis